980 related articles for article (PubMed ID: 33525754)
21. Co-Localization of Glia Maturation Factor with NLRP3 Inflammasome and Autophagosome Markers in Human Alzheimer's Disease Brain.
Ahmed ME; Iyer S; Thangavel R; Kempuraj D; Selvakumar GP; Raikwar SP; Zaheer S; Zaheer A
J Alzheimers Dis; 2017; 60(3):1143-1160. PubMed ID: 28984607
[TBL] [Abstract][Full Text] [Related]
22. The role of dopamine in NLRP3 inflammasome inhibition: Implications for neurodegenerative diseases.
Possemato E; La Barbera L; Nobili A; Krashia P; D'Amelio M
Ageing Res Rev; 2023 Jun; 87():101907. PubMed ID: 36893920
[TBL] [Abstract][Full Text] [Related]
23. The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson's disease via the microglial NLRP3 inflammasome.
Kou L; Chi X; Sun Y; Han C; Wan F; Hu J; Yin S; Wu J; Li Y; Zhou Q; Zou W; Xiong N; Huang J; Xia Y; Wang T
J Neuroinflammation; 2022 Jun; 19(1):133. PubMed ID: 35668454
[TBL] [Abstract][Full Text] [Related]
24. p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease.
Chen J; Mao K; Yu H; Wen Y; She H; Zhang H; Liu L; Li M; Li W; Zou F
J Neuroinflammation; 2021 Dec; 18(1):295. PubMed ID: 34930303
[TBL] [Abstract][Full Text] [Related]
25. Amyloidogenic proteins associated with neurodegenerative diseases activate the NLRP3 inflammasome.
Shao QH; Zhang XL; Yang PF; Yuan YH; Chen NH
Int Immunopharmacol; 2017 Aug; 49():155-160. PubMed ID: 28595078
[TBL] [Abstract][Full Text] [Related]
26. Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of β-arrestin2 and NLRP3.
Zhu J; Hu Z; Han X; Wang D; Jiang Q; Ding J; Xiao M; Wang C; Lu M; Hu G
Cell Death Differ; 2018 Nov; 25(11):2037-2049. PubMed ID: 29786071
[TBL] [Abstract][Full Text] [Related]
27. NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson's Disease.
Han QQ; Le W
Neurosci Bull; 2023 May; 39(5):832-844. PubMed ID: 36757612
[TBL] [Abstract][Full Text] [Related]
28. Involvement of NLRC4 inflammasome through caspase-1 and IL-1β augments neuroinflammation and contributes to memory impairment in an experimental model of Alzheimer's like disease.
Saadi M; Karkhah A; Pourabdolhossein F; Ataie A; Monif M; Nouri HR
Brain Res Bull; 2020 Jan; 154():81-90. PubMed ID: 31715312
[TBL] [Abstract][Full Text] [Related]
29. Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson's Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment.
Que R; Zheng J; Chang Z; Zhang W; Li H; Xie Z; Huang Z; Wang HT; Xu J; Jin D; Yang W; Tan EK; Wang Q
Front Immunol; 2021; 12():794770. PubMed ID: 34925379
[TBL] [Abstract][Full Text] [Related]
30. Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease.
Pike AF; Longhena F; Faustini G; van Eik JM; Gombert I; Herrebout MAC; Fayed MMHE; Sandre M; Varanita T; Teunissen CE; Hoozemans JJM; Bellucci A; Veerhuis R; Bubacco L
J Neuroinflammation; 2022 Feb; 19(1):50. PubMed ID: 35172843
[TBL] [Abstract][Full Text] [Related]
31. Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson's disease.
Fan Z; Pan YT; Zhang ZY; Yang H; Yu SY; Zheng Y; Ma JH; Wang XM
J Neuroinflammation; 2020 Jan; 17(1):11. PubMed ID: 31915018
[TBL] [Abstract][Full Text] [Related]
32. The Role of the Inflammasome in Neurodegenerative Diseases.
Piancone F; La Rosa F; Marventano I; Saresella M; Clerici M
Molecules; 2021 Feb; 26(4):. PubMed ID: 33670164
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases.
Jahan S; Kumar D; Chaturvedi S; Rashid M; Wahajuddin M; Khan YA; Goyal SN; Patil CR; Mohanraj R; Subramanya S; Ojha S
Curr Med Chem; 2017; 24(16):1645-1670. PubMed ID: 28245768
[TBL] [Abstract][Full Text] [Related]
34. Quinones as preventive agents in Alzheimer's diseases: focus on NLRP3 inflammasomes.
Chen DB; Gao HW; Peng C; Pei SQ; Dai AR; Yu XT; Zhou P; Wang Y; Cai B
J Pharm Pharmacol; 2020 Nov; 72(11):1481-1490. PubMed ID: 32667050
[TBL] [Abstract][Full Text] [Related]
35. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration.
Lee E; Hwang I; Park S; Hong S; Hwang B; Cho Y; Son J; Yu JW
Cell Death Differ; 2019 Jan; 26(2):213-228. PubMed ID: 29786072
[TBL] [Abstract][Full Text] [Related]
36. Targeting the NLRP3 Inflammasome in Neuroinflammation: Health Promoting Effects of Dietary Phytochemicals in Neurological Disorders.
Hung WL; Ho CT; Pan MH
Mol Nutr Food Res; 2020 Feb; 64(4):e1900550. PubMed ID: 31675164
[TBL] [Abstract][Full Text] [Related]
37. Pyroptosis in Alzheimer's disease: cell type-specific activation in microglia, astrocytes and neurons.
Moonen S; Koper MJ; Van Schoor E; Schaeverbeke JM; Vandenberghe R; von Arnim CAF; Tousseyn T; De Strooper B; Thal DR
Acta Neuropathol; 2023 Feb; 145(2):175-195. PubMed ID: 36481964
[TBL] [Abstract][Full Text] [Related]
38. From inflammasome to Parkinson's disease: Does the NLRP3 inflammasome facilitate exosome secretion and exosomal alpha-synuclein transmission in Parkinson's disease?
Si XL; Fang YJ; Li LF; Gu LY; Yin XZ; Jun-Tian ; Yan YP; Pu JL; Zhang BR
Exp Neurol; 2021 Feb; 336():113525. PubMed ID: 33161049
[TBL] [Abstract][Full Text] [Related]
39. NLRP3 Inflammasome: A Starring Role in Amyloid-β- and Tau-Driven Pathological Events in Alzheimer's Disease.
Van Zeller M; Dias D; Sebastião AM; Valente CA
J Alzheimers Dis; 2021; 83(3):939-961. PubMed ID: 34366341
[TBL] [Abstract][Full Text] [Related]
40. Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases.
Wu AG; Zhou XG; Qiao G; Yu L; Tang Y; Yan L; Qiu WQ; Pan R; Yu CL; Law BY; Qin DL; Wu JM
Ageing Res Rev; 2021 Jan; 65():101202. PubMed ID: 33161129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
